Дисертації з теми "Cancer de poumon"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 дисертацій для дослідження на тему "Cancer de poumon".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Meary, Alexandre. "Schizophrenie et cancer du poumon." Paris 6, 2001. http://www.theses.fr/2001PA062055.
Benizri, Emmanuel. "HIF-1alpha : le poumon du cancer." Nice, 2007. http://www.theses.fr/2007NICE4044.
Any alive organism can survive without energy, which involves a satisfactory oxygen and nutriments supply. At the initial phase of tumor progression, cells proliferate without their own vascularization ; indeed, oxygen and nutrients are delivered by simple diffusion. Nevertheless, beyond a certain size, these mechanisms are no more effective and oxygen deficiencies appear. The transcription factor HIF (Hypoxia Inducible Factor) is a key regulator required to maintain oxygen homeostasis. HIF is composed of a constitutive HIF-â sub-unit and a HIF- 1á sub-unit, specific of the hypoxic cascade. Three hifá genes have been identified : hif1a, epas 1 and hif3a that code for HIF-1á, HIF-2á and HIF-3á, respectively. Because of its ubiquitous tissue distribution and its central impact on the regulation of the target genes, HIF- 1á is the mosty studied isoform. During my laboratory training, I have contributed to 3 main projects : • First, I have been focused on the regulatory mechanisms that control HIF-1á stability and more precisely, on the study of the HIF prolyl-hydroxylase (PHDs). Using a RNA interference (RNAi) approach, we have highlighted PHD2 as the key isoform that controls HIF-1á stability in normoxia. Related to clinical studies, we have evaluated the impact of HIF-1á immunostaining in a serie of breast cancer. We have shown that HIF-1á is an independent prognostic factor and a bad preditive factor for classical adjuvant treatments. • Finally, in a pre-clinical study, we have analyzed the impact of HIF-1á invalidation by RNAi in a xenograft melanoma model. We have reported a reduction of tumor growth in mice treated with siRNAs targeting HIF-1á
Michel, Noémie. "Analyse de la contribution des kallicréines tissulaires 6 et 12 à la physiopathologie pulmonaire." Thesis, Tours, 2013. http://www.theses.fr/2013TOUR3303/document.
Recently, human tissue kallikreins (KLK) emerged as a new family of serine proteases which might play a major role in the tumorigenesis. The project aims at determining the contribution of KLK6 and 12 in lung pathophysiology. We showed that ectopic KLK6 promoted A549 cell proliferation in a protease activity-dependant manner, inhibited cell apoptosis and induced β-catenin nuclear translocation. Furthermore, this study uncovered a signaling pathway mediated by KLK6 in promoting A549 cell proliferation trough activation of the PAR2-EGFR-ERK pathway.We have also identified novel substrates of KLK12, the CCN family. We reported that KLK12-mediated proteolysis of CCN1 and CCN5 can reduce or abolish the binding of VEGF, BMP2, and TGF-β1
Pardo, Olivier. "Thérapie génique du cancer du poumon par la HSP65." Paris 5, 1997. http://www.theses.fr/1997PA05P120.
Derniame, Sophie. "Cancer du poumon / Réponse immunitaire locale - modulation tumeur dépendante." Nancy 1, 2006. http://docnum.univ-lorraine.fr/public/SCD_T_2006_0097_DERNIAME.pdf.
Lung cancer is the most frequent type of cancer in the world. Smoking is clearly the major cause of this pathology. The proliferation of tumor cells induces an inflammatory stromal reaction comprising numerous tumor-infiltrating lymphocytes. In this study, four complementary approaches have been used to study the tumor-dependent modulation of the immune system : TCR Vβ repertoire usage in flow cytometry, TCRγ gene clonal rearrangements in denaturing gradient gel electrophoresis (DGGE/TTGE), tumor and healthy lung tissue infiltration as well as lymph nodes characteristics in immunohistology and cytokine production by RNA RT-PCR. The results obtained have demonstrated the oligoclonality of T-cells in the three types of tissues tested. A Vβ13. 1 clone and a gamma clone appeared to be specifics of epidermoid carcinoma. Similarly, two TCRγ clones appeared to be restricted to adenocarcinoma. Moreover, the CD3/TCR complex was clearly down regulated in tumors compared to healthy tissue or lymph nodes. Similarly, HLA-DR, HLA-DQ and β2 microglobuline, strongly expressed on healthy pneumocytes were nearly absent from tumor cells. Several cytokines with antagonistic effects were detected within tumoral tissue, especially TGFβ and IL-10, which favour tumor growth and TNFalpha and IFNγ which potentialize the anti-tumoral immune response. In conclusion, the clones identified in healthy lung tissue could be specific of early pre-tumoral lesions induced by tobacco smoke, and some of the clones appear to be tumor-specific. However, the immune system has been defeated by several mechanisms, including a decrease of the expression of partners of the immunological synapse and the production of antagonistic cytokines
CAILLET, BRUNO. "Genetique et cancer du poumon : interet des etudes familiales." Lyon 1, 1991. http://www.theses.fr/1991LYO1M273.
Sève, Pascal. "Pharmacorésistance et cancer du poumon Non à petites cellules." Lyon 1, 2006. http://www.theses.fr/2006LYO10008.
Cauchi, Stéphane. "Etude des polymorphismes génétiques du récepteur aux hydrocarbures polycycliques aromatiques (AHR) et de son répresseur (AHRR) : relation avec l'inductibilité du CYP1A1 et le cancer pulmonaire." Paris 5, 2003. http://www.theses.fr/2003PA05N030.
Polycyclic aromatic hydrocarbons (PAH) found in cigarette smoke play a key role in the appearance of the lung cancer at the smokers. Cytochrome P-4501A1, metabolizes these HPA like benzo(a)pyrene in reactive and mutagen compounds. The CYP1A1 is inductible by the HPA and others compounds like dioxine. This inductibility is itself variable and largely dependent on the receptor Ah (AhR). The AhR is partially responsible for a polymorphic expression of the CYP1A1 and thus could be an important factor in carcinogenicity. We investigated the genetic polymorphisms of the AhR gene in a case-control study of lung cancer. Two new polymorphisms were found, none of them were found to play a key role. . .
RUGGIERI, SOPHIE. "Traitement des cancers du poumon non anaplasiques, non resecables, non metastatiques : a propos de 505 cas." Angers, 1989. http://www.theses.fr/1989ANGE1084.
TLEMSANI, LARBI. "Prise en charge du cancer du poumon au centre hospitalier general de cahors de 1989 a 1992." Toulouse 3, 1993. http://www.theses.fr/1993TOU31084.
Blaise, Françoise. "Mécanismes de reconnaissance dans les processus métastatiques : caractérisation d'une lectine membranaire des cellules du carcinome pulmonaire de Lewis." Orléans, 1986. http://www.theses.fr/1986ORLE0411.
Westeel, Virginie. "Prise en charge des cancers bronchiques : de l'approche individuelle à l'approche populationnelle." Besançon, 2001. http://www.theses.fr/2001BESAA006.
Because of the severity of both small cell (SCLC) and non-small cell lung cancer (NSCLC), development of more effective and less toxic treatments is required and the whole Jung cancer care has to be improved. ~ A. Follow-up program consisting of physical examination, chest roentgenogram, thoracic computed tomographie scan and fiberoptic bronchoscopy has been evaluated in 192 patients after complete resection for NSCLC. Ln a multivariate analysis, patients whose recurrence was asymptomatic had a significantly better survival with a relative risk (RR) of 0. 46 (95 % confidence interval (95 % CI) = 0. 29-0. 73; p<10-3). - An analysis comparing survival of Jung cancer patients in rural and urban areas was performed on 2 668 cases collected by the Doubs Cancer Registry between 1981 and 1996. Ln a multivariate analysis of observed and relative survival, very rural residence (RR = 1. 4 ; 95 % CI = 1. 11-1. 7; P = 0. 004 et 0. 006, respectively), age equal or greater than 65 years and small cell type were bad prognostic factors. - These results show that forlung cancer prognosis to be improved, efficacy of individual care must be increased and optimal cancer care uniformly provided to the whole population
Gratas-Rabbia-Ré, Catherine. "NSCLC N6 (carcinome bronchopulmonaire non à petites cellules) : nouveau modèle expérimental d'origine humaine pour la détection et l'étude de produits potentiellement anticancereux." Nantes, 1989. http://www.theses.fr/1989NANT03VS.
Thibaut, Béatrice. "Suivi thérapeutique de cancers pulmonaires inopérables et/ou polymétastasés : essai préliminaire chez vingt trois patients traités par polychimiothérapie." Paris 5, 1990. http://www.theses.fr/1990PA05P014.
Boldea, Vlad. "Intégration de la respiration en radiothérapie : apport du recalage déformable d'images." Lyon 2, 2006. http://theses.univ-lyon2.fr/documents/lyon2/2006/boldea_v.
A major challenge in lung cancer treatment in radiotherapy is to take into account organs movements and deformations in order to improve dose coverage of the tumor and spare the surrounding healthy tissues. We focused on intensity based deformable registration methods applied to 3D computed tomography scans (3D-CT) of the thorax. The goal is to extract movement and deformation information of lungs and tumor. During this PhD we developed a deformable registration platform with multiples regularizations techniques of vector fields. We did three main studies. In the first one we used deformable registration to study the breath-hold reproducibility with ABC device. The breath-hold was efficient for patients with normal lung behavior and inefficient for patients with lung discrepancies. In the second study, we used 4D-CT acquisitions (a 4D-CT acquisition is a set of 3D-CT images acquired over the free-breathing respiration cycle). The goal was to extract and follow thorax movements for a free-breathing treatment and 4D dosimetric studies. We built a first 4D-CT image model with two 3D-CT images acquired at end-inhale and end-exhale stages of the respiration cycle. The long-term goal is to have a complete model of lung and thorax, allowing tumor tracking and respiration synchronized irradiation, in order to optimize the lung cancer treatment in radiotherapy
Paul, Sylvain. "Cancer anaplasique à petites cellules du poumon et du pancréas : à propos d'un cas de survie prolongée (46 mois)." Montpellier 1, 1989. http://www.theses.fr/1989MON11035.
Papadopoulos, Alexandra. "Facteurs de risque de cancer du poumon chez la femme." Phd thesis, Université Paris Sud - Paris XI, 2012. http://tel.archives-ouvertes.fr/tel-00772692.
Martin, Marie-Claude. "Cancers broncho-pulmonaires primitifs chez les sujets de 75 ans et plus." Bordeaux 2, 1999. http://www.theses.fr/1999BOR2M111.
Sirgant, Xavier. "Aspects cliniques des métastases pleuro-pulmonaires : à propos de 95 cas." Bordeaux 2, 1990. http://www.theses.fr/1990BOR25118.
Martins, Helder Manuel. "Cancers broncho-pulmonaires secondaires à une radiothérapie ou à une chimiothérapie : à propos de 4 observations." Saint-Etienne, 1988. http://www.theses.fr/1988STET6051.
Chomy, Isabelle. "Métastases rénales de tumeurs solides : à propos de trois cas de cancers broncho-pulmonaires : revue de la littérature." Bordeaux 2, 1989. http://www.theses.fr/1989BOR25227.
Alauzen, Michel. "Contribution à l'étude du syndrome de Pancoast et Tobias : à propos de 11 cas opérés." Montpellier 1, 1989. http://www.theses.fr/1989MON11291.
Van, Huffel Serge. "Traitement des carcinomes bronchiques primitifs non à petites cellules : à propos d'une série hospitalière de 292 cas." Bordeaux 2, 1991. http://www.theses.fr/1991BOR23017.
Lasolle, Christophe. "Métastases digestives des cancers bronchiques : à propos de deux cas cliniques." Nancy 1, 1992. http://www.theses.fr/1992NAN1A002.
RAOUX, ANDREE. "Association sclerodermie - cancer du poumon : revue de la litterature ; a propos d'une observation." Aix-Marseille 2, 1992. http://www.theses.fr/1992AIX20853.
MAGNIN, JEAN-LUC. "Etude de la survie a deux ans des cancers du poumon non anaplasiques a petites cellules non resecables non metastases." Aix-Marseille 2, 1989. http://www.theses.fr/1989AIX20079.
Lemonde, Manon. "Qualité de vie de personnes atteintes de cancer du poumon avancé." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0026/NQ51960.pdf.
Pinot, Roussel Hélène. "Étude du microenvironnement immunitaire des tumeurs du poumon avec réarrangement ALK et rôle des lymphocytes résidents mémoires dans les tumeurs muqueuses (poumon, ORL)." Thesis, Sorbonne Paris Cité, 2016. http://www.theses.fr/2016USPCB086.
Lung cancer is the most common cause of cancer-related mortality worlwide and a therapeutic challenge. Approximately 5% to 6% of non-small cell lung carcinoma (NSCLC) have chromosomal rearrangements of the anaplastic lymphoma kinase (ALK) gene, which mainly involve the echinoderm microtubule–associated protein-like 4 (EML4) gene as a partner. Even if the ALK tyrosine kinase inhibitor (TKI), crizotinib, has been successfully developed in these patients, resistance invariably occurs leading to tumor relapse. The ALK rearranged protein is immunogenic, was shown to induce PD-L1 and highlight the potential of immunotherapy in this cancer. The first issue of our work was to set up an immunofluorescence multiplex platform to comprehensively analyse the tumor microenvironment of a retrospective cohort of 29 ALK positive ADC, compared to 27 EGFR mutated ADC and 25 wild type ADC. Mean number of total CD8+T cells expressing or not PD-1 and the ratio of CD8/regulatory T cells weren’t significantly different between the various subgroups. The percentage of tumor cells expressing PD-L1 were higher in the ALK positive ADC, than in the EGFR positive ADC or WT lung cancer. We found a significant correlation in ALK positive ADC between the number of total or intratumoral (intraT) CD8+ or PD-1+CD8+T and the expression of PD-L1 by tumor cells suggesting a possible role of adaptive immunity in the regulation of PD-L1 on these tumor cells. Furthermore, the percentage of patients displaying two criteria of clinical response (% PD-L1 on tumor cells and infiltration by intraT PD-1+CD8+ or CD8+T cells) was higher in the ALK positive ADC. According to our results, a subgroup of ALK rearranged lung ADC patients may represent good candidates to be treated by anti-PD-1/PD-L1 antibodies. The alveolar wall is a mucosal site in contact with the environment. Resident memory T cells (Trm) found most prominently at mucosal sites represent a new subset of long lived memory T cells that remain in tissue and do not recirculate. Due to their role in local immunity, strategies to elicit Trm after vaccination have been developed. We and others clearly showed that mucosal immunization were more efficient than the conventional systemic route (intramuscular, subcutaneous) to elicit Trm at the mucosal tumor site. Indeed, the mucosal route of immunization imprints T cells with a mucosal homing program defined by a profile of integrin and chemokine receptors promoting their homing to the site of initial activation. A correlation was observed between the ability to elicit these cells at the tumor site and the control of tumor growth. The second issue of this work was to characterize in a mouse model Trm after mucosal cancer vaccine administration and in human lung cancer. We first developed various original strategies (mucosal immunization, use of mucosal vector, modulation of TGF, parabiosis experiments) to elicit or inhibit Trm in a preclinical model of head and neck cancer. All these experiments converged to demonstrate that the induction of Trm are required for the control of tumor growth. In order to extrapolate this role of Trm in humans, we found that the number of Trm correlated with a better overall survival in lung cancer in multivariate analysis. The induction of Trm may represent a new surrogate biomarker for the efficacy of cancer vaccine
Massin, Frédéric. "Expression de tétraspanines et d'intégrines B1, et immunomodulation dans le cancer du poumon." Nancy 1, 2004. http://docnum.univ-lorraine.fr/public/SCD_T_2004_0248_MASSIN.pdf.
Dajon, Marion. "Rôle de TLR7 dans la progression tumorale dans le cancer du poumon." Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066272/document.
Numerous studies have implicated some TLR in tumor development. Previously, we have demonstrated that lung tumor cells express TLR7, a receptor for ssRNA, and that high TLR7 expression confers to NSCLC patients bad clinical outcome. In mice models of lung cancer, we further demonstrated that the injection of TLR7 agonists led to a pro-tumoral effect.My thesis work has firstly demonstrated the mechanisms involved in the pro-tumoral effects of TLR7 in lung cancer: TLR7 stimulation on tumor cells induces a high production of CCL2 and GM -CSF, as well as a sharp MDSC recruitment within the tumor. These MDSC, by their immunosuppressive properties, are implicated in the pro-tumoral effect upon TLR7 stimulation. We also demonstrated that TLR7 stimulation was pro-metastatic in a mice model of lung cancer and that MDSC were also involved in this effect. These pro-metastatic effects associated with TLR7 have been confirmed in humans through the studies of transcripts and proteins involved in invasion, angiogenesis, Epithelial–mesenchymal transition and metastasis. Finally, we demonstrated that TLR7 ligands are present in tumor microenvironment of lung cancer patients and that intratumoral injection of respiratory viral infections such as IAV and RSV, have a pro-tumoral effect in lung cancer mice model. These respiratory viruses could therefore be at the origin of the overexpression of TLR7 and the poor clinical outcome associated with this receptor in lung cancer patients. This research has thus made possible to highlight new aggravating factors in lung cancer, including respiratory viruses, and to discover the mechanisms involved
Nardoux, Joe͏̈lle. "Réactivité cutanée chez les cancéreux pulmonaires : contribution des biopsies cutanées." Montpellier 1, 1989. http://www.theses.fr/1989MON11213.
Rey, Jean-Pierre. "Nevrite optique retro-bulbaire paraneoplasique revelatrice d'un cancer micro-cellulaire du poumon." Lyon 1, 1988. http://www.theses.fr/1988LYO1M303.
POURCHOT, PANGRANI FABIENNE. "Coronaropathie et carcinome bronchopulmonaire : prise en charge diagnostique et therapeutique chirurgicale combinee." Nice, 1990. http://www.theses.fr/1990NICE6502.
TAVERNIER, MAXIME. "Place du scanner thoracique dans le bilan pre-operatoire des cancers broncho-pulmonaires non a petites cellules : a propos de 50 cas." Lyon 1, 1988. http://www.theses.fr/1988LYO1M481.
BALDUIN, MARIE-THERESE. "Radiotherapie a visee curative des cancers broncho-pulmonaires non a petites cellules t1n0 et t2n0 : a propos de 53 observations." Lyon 1, 1989. http://www.theses.fr/1989LYO1M169.
MOREAU, ERIC. "Les cancers broncho-pulmonaires primitifs successifs : a partir de 11 observations." Bordeaux 2, 1988. http://www.theses.fr/1988BOR25180.
TORTORELLI, SORAYA. "Le cancer bronchopulmonaire primitif chez le sujet age de 75 ans et plus : revue generale a propos d'une serie personnelle." Aix-Marseille 2, 1993. http://www.theses.fr/1993AIX20130.
Roche, Olivier. "Forme kystique des cancers broncho-pulmonaires primitifs : 5 observations cliniques et revue de la litterature." Université Louis Pasteur (Strasbourg) (1971-2008), 1990. http://www.theses.fr/1990STR1M189.
TIVOLLE, DENIS. "Cancer peripherique du poumon non micro-cellulaire operable avec metastase cerebrale unique et simultanee." Lyon 1, 1988. http://www.theses.fr/1988LYO1M258.
REVERTE, MARC LOUIS AUGUSTE. "Papillomatose cutanee floride revelatrice d'un cancer pulmonaire." Clermont-Ferrand 1, 1991. http://www.theses.fr/1991CLF13817.
Zangari, Joséphine. "Contribution du transfert du miR-223-3p des neutrophiles aux cellules tumorales dans la progression du cancer du poumon." Electronic Thesis or Diss., Nice, 2016. http://www.theses.fr/2016NICE4040.
Lung cancer is the leading cause of cancer mortality in France and worldwide. Today in France, the overall five-year survival rate after diagnosis is only 14%, making it one of the most challenging cancers to treat. Personalized medicine is now the preferred approach for lung cancer for metastatic stage, including so-called immunotherapy. Within a tumor, cancer cells are surrounded by an inflammatory microenvironment rich in polymorphonuclear neutrophils (PMN). While it is established that the presence of PMN is associated with the development of carcinomas, the contribution of intratumoral PMN and their interaction with cancer cells in tumor progression is unclear. To explore these hypotheses, objectives of our study were: 1) to decrypt the communication between neutrophils and tumor cells (miRNAs and microvesicles) and 2) the regulation of these actors in the recipient cells, 3) to demonstrate their role in tumor progression and dissemination. Tumor plasticity and invasion are part of the most important features of cancer progression. This work has allowed us to identify a new mechanism of transient acquisition of phenotype by transfer of extracellular miRNA (ex-miRNA) into cancer cells with and, importantly, by letting the ex-miRNA decay. We observed that the ex-miR-223-3p is transferred from PMN to lung tumor cells via exosomes. This transfer is functional, as demonstrated by the occurrence of epithelial to mesenchymal transition (EMT) associated with an invasive phenotype and inhibition of one of its targets, FOXO1 transcription factor
Gaillard, Annie. "Comparaison du dosage des IgE totales et spécifiques chez les bronchitiques chroniques et les patients atteints de néoplasie pulmonaire." Montpellier 1, 1988. http://www.theses.fr/1988MON11272.
Giroux, Leprieur Etienne. "Facteurs de résistance à la chimiothérapie à base de sels de platine dans les cancers bronchiques non à petites cellules : Rôle de la voie Sonic Hedgehog dans la chimiorésistance." Thesis, Paris 6, 2014. http://www.theses.fr/2014PA066223/document.
Non-small cell lung cancer (NSCLC) is known to be chemoresistant. Few robust markers of chemoresistance have been validated so far in this type of cancer. We have described in this work new innovative markers of resistance to cisplatin-based chemotherapy in NSCLC. After the study of usual clinical and molecular caracteristics of patients who were refractory to chemotherapy, we have then explored the role of the Sonic Hedgehog (Shh) pathway in NSCLC and its impact in term of chemoresistance. We have shown that Shh pathway, closely linked with cancer stem cells, was correlated with the refractory property to chemotherapy. Positive Gli2 immunohistochemistry score was associated with tumor progression et progression-free survival. We have also demonstrated a correlation between Shh activation and epithelial-mesenchymal transition, known to be linked with tumor aggressiveness, metastatic ability and chemoresistance. We have then validated the great role of Shh pathway in tumor proliferation and chemoresistance in another thoracic cancer, known to be chemoresistant, the malignant pleural mesothelioma. At last, the impact of ceancer stem cells on tumor aggressiveness and prognosis has been demonstrated through the study of the expression of hPAF1C (human polymerase II-associated factor 1 complex), described as overactivated in cancer stem cells and linked to Shh pathway activation. We have shown that hPAF1C expression was associated with poor prognosis and with tumor proliferation through an interaction with c-Myc. These results underline the major role of Shh pathway and cancer stem cells in SNCLC in term of chemoresistance and tumor aggressiveness
Dudoignon, Nicolas. "Analyse de la frequence d'apparition de tumeurs pulmonaires chez le rat apres exposition a des aerosols d'oxydes d'actinides : identification de facteurs de risque en comparant le npo2 et le puo2." Paris 5, 2001. http://www.theses.fr/2001PA05N035.
Eberst, Guillaume Nicolas. "Seconds cancers après traitement curatif d'un cancer broncho-pulmonaire." Electronic Thesis or Diss., Bourgogne Franche-Comté, 2023. http://www.theses.fr/2023UBFCE029.
The first objective of the 2014-2019 cancer plan was to cure more patients by promoting earlier diagnosis. This objective gives hope for more diagnosis at early stages accessible to surgical resection. Currently, excisional surgery for non-small cell bronchopulmonary cancer (NSCLC) is the treatment offering the most hope for a cure. This thesis work is particularly interested in the future of operated patients.Despite a curative intention, patients operated on for NSCLC are at risk of recurrence of the operated cancer but also have a higher risk of second cancer, and in particular second primary lung cancer (SPLC), higher than that of the general population. , of the order of 20% cumulative incidence at 10 years.When a lung lesion with the same histological diagnosis as the operated cancer occurs, the differential diagnosis between recurrence of the operated cancer or SPLC is difficult. Several definitions exist. Based on the hypothesis that recurrences indicate an aggressiveness of the cancerous disease, and therefore most often have a worse prognosis than second cancers, we first conducted a Cochrane systematic review of the set of definitions used in the literature in order to identify the one which offers the best prognostic distinction, on which to base the differential diagnosis between recurrence of operated cancer and SCBP.A few years ago, immunotherapy established itself in the therapeutic arsenal for bronchopulmonary cancer. First used in the metastatic situation, immunotherapy is now tested in the perioperative situation in numerous trials. However, due to the diversity of combinations and therapeutic strategies, not all of which have been compared with each other, uncertainty remains regarding the best perioperative therapy for patients undergoing surgery for early-stage NSCLC. We initiated a systematic review of interventional trials with network meta-analysis according to the Cochrane method on the effectiveness of these perioperative treatments in patients with non-small cell lung cancer.The IFCT-0302 study is the only large randomized surveillance study of NSCLC patients. It included 1775 patients. Its objective was to compare the overall survival of two monitoring strategies: by clinic and chest x-rays in the control group, and by clinic, chest x-rays and thoraco-abdominal scans in the experimental group. Patient-described quality of life (HRQoL) is a measure of three domains of perceived health: physical, social, and emotional. QoL is impacted by a medical condition or its treatment. Evidence suggests that lung cancer surgery has a significant impact on QoL. The objective of our work was to evaluate the influence of the type of surveillance on HRQoL in the population of the IFCT-0302 study.When an abnormal lung image is detected, its histological diagnosis is frequently obtained by transthoracic puncture guided by the scanner. The main complication of the procedure is pneumothorax. Hospital constraints do not allow all patients to be hospitalized after a transthoracic puncture. In this third axis, we worked on the validation of a predictive score for the occurrence of delayed pneumothorax after a CT-guided transparietal lung biopsy, in order to select patients who must be monitored in conventional hospitalization. This work was carried out on a cohort of patients from Besançon University Hospital, one part of the cohort having made it possible to develop the score, the other to validate it. Finally, external validation work on a cohort of patients from the Bichat – Claude Bernard Hospital was carried out
Cabelguenne, Arnauld. "GSTP1 et p53 : marqueurs prédictifs de la réponse à la chimiothérapie associant le 5-Fluorouracile et le Cisplatine dans les cancers des voies aérodigestives supérieures." Paris 5, 2003. http://www.theses.fr/2003PA05N109.
Optimization of therapeutic strategy requires prior determination of predictive parameters of patients' response to anti-cancer drugs. In head and neck cancer patients treated by induction chemotherapy based on Cisplatin and 5-Fluorouracil, we showed a link between the presence of allelic GSTP1105val and the more important presence of mutations in p53 gene, that GSTM1 gene deletion was a risk factor of laryngeal cancers (2,6 times), that chemotherapy response is associated with a low plasma level of GSTP1. Presence of p53 mutations led to a decrease of chemo-sensibility to CDDP and to 5-FU. We identified a significant difference between the presence of p53 mutations in responder patients and non-responder patients (61% versus 81%). Predict the response to chemotherapy is now possible
Germain, François. "L'utilisation de marges personnalisées dans le traitement du cancer du poumon en radiothérapie." Master's thesis, Université Laval, 2005. http://hdl.handle.net/20.500.11794/19429.
Individualized margins in radiotherapy planning of lung cancer: analysis of physiological movements and their dosimetric impacts OBJECTIVE: This study is an analysis of physiological movements and their dosimetric impacts when a single thoracic CT-scan is used for treatment planning purposes in radiation oncology. METHODS: This is a study of 15 patients. Three-dimensional conformal radiation therapy was (3D-CRT) was used. A reference clinical plan was constructed and compared with plans using individualized margins (obtained by using five CT-scans). Volumetric and dosimetric analyses were made for each. RESULTS: The total volume occupied by GTV progressed quickly with the fusion of CT-scans. For a similar coverage, target volume was smaller and lung irradiation was slightly decreased. CONCLUSIONS: Even if the individualized margin was used, it produced a limited clinical advantage. All techniques that increase total volume with an aim to include more movements should come to similar conclusions.
Mennecier, Gregory. "Etude de mécanismes moléculaires associés à l’effet suppresseur de tumeur des connexines 30 et 43." Poitiers, 2006. http://www.theses.fr/2006POIT2368.
Depontieu, Florence. "Endocan : un médiateur du dialogue endothélial dans le cancer et le sepsis." Lille 2, 2006. http://www.theses.fr/2006LIL2S065.
Vieira, Thibault. "Caractérisation des carcinomes sarcomatoïdes primitifs pulmonaires." Thesis, Paris 6, 2016. http://www.theses.fr/2016PA066552/document.
Sarcomatoid carcinomas are a rare subtype of non-small cell lung cancer (NSCLC). Prognostic seems less favourable than other subtypes of NSCLC. Our team works to determine molecular characteristics of these tumors. In this work, we demonstrated that sarcomatoid carcinomas are chemoresistant to platinum based regimen in vitro and in vivo (primary cell lines) compared to other NSCLC. We demonstrated that this tumors share immunohistchemical, moleculary similarities with NSCLC validating the WHO classification. It is possible that these tumors came from cancer stem cell or underwent an epithelial-mesenchymal transition. Specificities of this transition remained undefined. Moreover these tumors presented a lot of molecular alterations allowing to investigate targeted therapies such as MET inhibitors. At last, we shows the implication of the immune system, the strong infiltration of TCD8+ lymphcoytes CD163+ macrophages and the expression of PD-L1, allowing to hope new perspective of research, innovative treatment